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Abstract 
Objective: To develop and undertake initial validation of a patient-reported outcome measure 
(PROM) to assess health-related quality of life in patients with breast cancer-related upper limb 
lymphedema (ULL). 
Study Design and Setting: We developed and validated the Upper Limb Lymphedema Quality of Life 
(ULLQoL) scale in two stages: devising the items and pre-testing with patients and clinicians; 
longitudinal validation to test its psychometric properties - underlying dimensions, internal 
consistency, test-retest reliability, construct validity, and responsiveness. Patients with ULL were 
recruited from two out-patient clinics. 
Results: We derived the ULLQoL scale from a pool of 98 items generated by patients. After further 
consultation we produced the draft ULLQoL scale. For validation 103 patients with ULL completed 
the draft scale and two generic health measures: SF-36 and ED-5D-3L. Psychometric analysis 
identified two components, physical and emotional well-being, with good internal consistency and 
test-retest reliability. Significant correlations with SF-36, EQ-5D-3L, and percentage excess limb 
volume confirmed construct validity. The ULLQoL scale showed good responsiveness to change 
reported by lymphedema patients and moderate to large effect sizes. 
Conclusion: The 14-item ULLQoL scale is a robust upper limb lymphedema-specific measure that is 
feasible and valid to use in both the clinical and research settings.  
 
Keywords: quality of life, lymphedema, development, psychometric analysis, patient-reported 
outcome measure, breast cancer. 
 
Running title: Measurement of breast cancer-related upper limb lymphedema quality of life 
 
Abstract word count: 199 words 
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1. Introduction 
A simple definition of lymphedema is: ‘a chronic swelling of an organ or a tissue due predominantly 
to an impairment of lymph drainage’ [1] (p. 213). Lymphedema is a progressive condition with 
excess tissue oedema being the predominant feature during the early stages [2]. The limb is soft and 
pitting, and the excess tissue oedema may reduce when the limb is elevated [2]. As the condition 
advances, it can be differentiated from other types of oedema because the limb becomes firm, non-
pitting and fibrotic, with deepened natural skinfolds.  
 
There are primary and secondary causes of lymphedema, but in developed countries, lymphedema 
is usually secondary to treatment for cancer [3]. The focus of this study is upper limb lymphedema 
(ULL), the predominant cause of which is treatment for breast cancer. Lymphedema is a potential 
lifelong concern for women who survive breast cancer; estimates suggest “that about 20% of 
women will develop arm lymphedema after breast cancer” [4] (p. 500). Considerable morbidity is 
associated with ULL, as reported by studies of the lived experience of lymphedema, including impact 
on physical function, social function, emotional well-being and body-image [5-9].  
 
Given the potential effect of ULL on patients’ quality of life, ‘Best Practice for the Management of 
Lymphedema’ suggested that the assessment of patients should extend beyond the location and 
extent of limb swelling and include assessment of the ‘morbidity impact’, that is psychosocial status, 
mobility and function [3]. We know of eight lymphedema-specific measures of Health-related 
Quality of Life (HRQOL). Four of these are not specific to ULL, one is specific to cancer-related 
lymphedema, one is specific to breast-cancer-related lymphedema and two are specific to ULL (Table 
1). However, none of these measures meet all of Terwee et al.’s (2007) quality criteria [10] and the 
COSMIN methodological checklist [11]. Indeed, four of the measures failed to meet any of these 
quality criteria, and methodological quality was generally rated as ‘poor’ or ‘fair’.  
 
The most robust measure specific to ULL when assessed against Terwee et al.’s (2007) [10] quality 
criteria and the COSMIN methodological checklist [11] is the ULL27, developed in French and 
sponsored by the French Lymphology Society. Although detailed information is available of the 
development of the ULL27 to support its content validity, psychometric analysis has only been 
reported from an interim analysis of the validation study [12], with no continuation of the work to 
provide the full analysis of this initial validation study. The development of the 38-item LYMQOL-arm 
has been reported along with information on its measurement properties [13]. Though the 38-item 
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version of the LYMQOL-arm was reduced to 28 items, the measurement properties of the 28-item 
version have not been evaluated by the developers [14].  
 
The remaining incompleteness of the initial psychometric validation studies for the ULL27 and the 
LYMQOL-arm means that there is still a need for a well-validated tool to assess quality of life in 
patients with ULL. The need to reflect patients’ experiences and views led us to develop a patient-
reported outcome measure (PROM) specific to the assessment of HRQoL associated with ULL and to 
assess its psychometric measurement properties, including an estimate of the minimal clinical 
difference. We referred to the person’s perception of well-being as it specifically and directly relates 
to their health as our definition of HRQoL in the development process [15]. 
 
2. Materials and methods 
We followed the approach set out by Streiner et al. [16] for the development and validation of 
health measurement scales.  
 
2.1 Devising the items and pre-testing 
To derive the items for our ULL PROM we undertook a literature review and consulted a 
convenience sample of patients with ULL who were attending routine out-patient appointments at 
Sir Michael Sobell House Lymphedema Clinic in Oxford. All patients approached during the week 
agreed to participate in the study. We asked patients to list the five most important everyday 
activities that had been affected by ULL in the last month.  
 
We grouped the activities into concepts of interest and relevance, and noted the number of 
activities in each concept. Items considered irrelevant to quality of life associated with ULL were 
discarded. We organised the remaining items into an initial scale (version 0) using a 5-point, 
adjectival rating scale which enabled patients to rate the effect of ULL on each item over the 
previous two weeks. To pre-test the scale we asked a different convenience sample of patients with 
ULL and 25 lymphedema specialist therapists to complete this initial version of the scale, and to 
comment on face and content validity, wording and acceptability. This feedback enabled us to 
update the scale to version 1 for the validation study. 
 
2.2 Validation study 
The validation study comprised a longitudinal study a test-retest study after two weeks. We worked 
with patients from two established out-patient Lymphedema Clinics in Cambridge. Patients aged 18 
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years or older with ULL were eligible for the study. We excluded vulnerable patients, for example 
those with a life expectancy less than six months, psychiatric morbidity, learning difficulties, or poor 
comprehension of English. We approached eligible patients and gained their consent to participate 
in the study.  
 
At the initial visit we asked these consented participants to complete version 1 of the ULLQoL scale, 
a socio- demographic form, and two generic health outcome measures - the SF-36 [17] and EQ-5D-3L 
[18], and measured their limb volume. To assess the test-retest reliability of the ULLQoL scale we 
sent a subsample of participants a second questionnaire two weeks after their initial visit. We asked 
patients to complete and return all three questionnaires, and assess whether they judged that their 
condition had improved, remained the same, or deteriorated since their initial visit. We collected 
further data from participants at an outpatient visit three to six later, which was used to assess 
responsiveness.  We asked them to complete all of the questionnaires again and comment on 
whether their condition had changed since their initial visit. We measured their limb volume again.  
 
We completed a formal pilot lasting ten weeks to check recruitment rates. A retrospective review of 
the clinic diary suggested that one could recruit about two patients a week. So we expected to 
recruit 20 patients after ten weeks, and to complete recruitment after about one year. We also 
checked the appropriateness and feasibility of this design with the staff, and made a preliminary 
check whether they were using the full range of responses of the newly devised PROM.   
 
Sample size 
The literature recommends that for validating PROMs a sample size of between 50 and 100 patients 
is required [10, 16]. Nunnally [19] suggested a ratio of five to ten patients per item. Based on this, 
we aimed to recruit at least 100 patients over a one-year period for the purpose. 
 
Ethical Considerations 
All management staff at the two Lymphedema Clinics agreed to participate and to allow their 
patients’ to participate in the study. When generating items, we sat down with each patient and 
explained the purpose of the task to the patients and invited them to give oral consent to take part 
which we then documented. We told patients that they were under no obligation to participate and 
that refusal would not affect their treatment within the clinic. The Cambridge Research Ethics 
Committee (LREC 97/165) gave a favourable ethical opinion on the validation study. We gave all 
potential participants a Patient Information Sheet describing the purpose of the study, what their 
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role would be, and the practicalities of participation. We explained the ethical aspects of 
confidentiality and anonymity and asked patients wishing to participate to sign consent forms. 
  
2.3 Statistical analysis 
We analysed the data using the Statistical Package for Social Sciences (SPSS version 22).  
 
2.3.1 Item selection and assessment of underlying dimensions 
We considered items for inclusion in the ULLQoL scale by assessing their item completion rates and 
frequency of endorsement, and whether they performed consistently. We considered individual 
items for rejection if more than 5% of their data were missing [16]. We set the target endorsement 
rate at between 20% and 80%, and considered rejecting items outside the range, suggesting risk of 
‘floor’ or ‘ceiling’ effects [16]. We used item-total correlations below 0.2 to identify items 
inconsistent with the others, and therefore candidates to be discarded [20]. 
 
We used principal component analysis (PCA) to assess the underlying dimensions of the ULLQoL 
scale. To check the suitability of the data for PCA, we initially undertook an unrotated exploratory 
PCA. We examined the Kaiser-Meyer-Olkin Index [21] and Bartlett’s test of sphericity [22] using a 
threshold of 0.5 to explore whether the sample size was suitable [23]. In preliminary analysis we 
required that eigenvalues of important components should clearly exceed 1.0 [24]. We also 
suggested that factor loadings should exceed 0.4 to retain items in components [16]. Having 
determined the components, our next step was to improve these by rotation. We chose to use an 
oblique rotation of the factors to allow for the possibility that components were related rather than 
orthogonal to each other. An assessment of the face validity of items and components also 
contributed to the identification of the underlying principal components; items and components 
needed to be a recognisable aspect of a patient’s health and well-being, the naming of the 
components being subjective.    
 
2.3.2 Calculation of scores for ULLQoL scale 
We imputed missing items by the lowest available score, thus underestimating the item score [16]. 
We calculated total scores and dimension scores for the ULLQoL scale by giving equal weight to each 
item and, summing the item scores. Thus the total score for the ULLQoL scale ranged from 0 to 56, 
with lower scores showing better QoL. As the physical well-being dimension comprised 9 items, 
scores potentially ranged from 0 to 36; as the emotional well-being dimension comprised 5 items, 
scores potentially ranged from 0 to 20.  
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2.3.3 Psychometric properties of the ULLQoL scale 
We tested the internal consistency of the components of the ULLQoL scale by Cronbach’s alpha 
statistic [25], using a threshold of 0.7 as evidence of consistency for a research tool and 0.9 as 
evidence for a clinical tool [19]. We assessed test-retest reliability by analysing change in the ULLQoL 
scale scores of participants who reported that their lymphedema had not changed over time [26]. 
We chose an interval of two weeks to minimise a participant’s ability to recall their previous 
response while maximising the chance that their health had indeed remained stable. We assessed 
reliability using the intra-class correlation coefficient, and used an alpha of 0.7 as the threshold for 
reliability. 
 
We assessed construct validity of the ULLQoL scale by the strength and direction of the correlation 
with other attributes, both similar and dissimilar [16]. We categorised correlations greater than 0.7 
as showing strong relationships; those between 0.5 and 0.7 as moderate relationships; those 
between 0.3 and 0.5 as weak relationships; and those less than 0.3 as very weak relationships [27]. 
From our clinical experience of ULL, we predicted moderate correlations between the physical well-
being and emotional well-being dimensions of the ULLQoL scale; but very weak correlations 
between both dimensions of the ULLQoL scale and limb volume, the traditional measure of severity 
of lymphedema. It is not just the size of the swollen arm that could interfere with physical and 
emotional well-being, but also should stiffness, pain and swollen fingers and hand. Considering the 
content of the generic PROMs we also predicted moderate correlations between the ULLQoL scale 
physical well-being dimension and the EQ-5D-3L utility score, the EQ-5D thermometer and the 
physical well-being dimension of the SF-36; but weak correlation with the mental well-being 
dimension of the SF-36. We predicted weak correlations between the emotional well-being 
dimension of the ULLQoL scale and the EQ-5D-3L utility score, and the mental well-being dimension 
of the SF-36; but even weaker correlation with the physical component of the SF-36.  
 
We assessed the responsiveness of the ULLQoL scale, that is its ability to detect change in patients’ 
well-being, by examine correlation of changes scores as well as providing the effect size statistic 
using the Modified Standardised Response Mean (MSRM) for the ULLQoL. The MSRM is calculated 
by dividing the mean change score by the standard deviation of change in patients who report the 
lymphedema to be stable [28]. Following the criteria of Cohen [29] we categorised changes of the 
order of one-fifth of a standard deviation as small, those about one-half a standard deviation as 
moderate, and those about four fifths of a standard deviation as large. We conducted an initial 
estimate of the minimal important change (MIC) calculating the one-half standard deviation (SD). 
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3. Results 
3.1 Devising the items and pre-testing 
We found little information in the literature at the start of PROM development. We recruited 24 
female patients, aged between 48 and 72 years old and diagnosed with breast cancer-related 
lymphedema ULL, to suggest relevant items. They offered a total of 98 everyday activities affected 
by ULL. Two items were discarded as we considered them to be irrelevant to upper limb 
lymphedema-specific HRQoL - “worry about cancer returning” and “financial worries” both of which 
relate to cancer rather than lymphedema. Both of the items were also only identified by one patient. 
With the remaining 96 items we went one-by-one and grouped similar concepts. We derived 12 
distinct concepts and the number of activities in each concept ranged from 3 to 18 activities. We 
then converted the concepts into questions about respondents’ experiences: eight starting: " During 
the past two weeks to what extent _ _ _  ?" and four starting: "During the past two weeks how much 
of the time _ _ _ ?" (ULLQoL version 0). We considered a recall interval of two-weeks was 
appropriate to measure the concept of HRQoL and for the condition [30]. Furthermore, we 
considered the target group to be capable of recalling the past two weeks in relation to the item 
content.  For response categories we adopted a 5-point scale: for the eight magnitude questions – 
“not at all”, “a little bit”, “moderately”, “quite a bit” and “extremely”; and for the four frequency 
questions: “none of the time”, “some of the time”, “a good bit of the time”, “most of the time” and 
“all of the time”.  
 
To pre-test the ULLQoL scale (version 0) the first five patients who attended a routine lymphedema 
out-patient appointment all agreed to participate, as well as 16 of 25 (64%) lymphedema specialist 
therapists. The patients confirmed face and content validity and made no recommendations for 
changes to item wording, finding all of the items acceptable. Unaided completion of version 0, 
including reading the instructions took between two and four and a half minutes. The lymphedema 
specialist therapists suggested the addition of an item to capture relationship difficulties with their 
partners to complete content validity as they reported that this arises in conversation with patients 
in routine clinical practice and affects their HRQoL. An item asking ‘to what extent did your swollen 
arm interfere with your sexuality’ was added to the PROM. The nurses also made two comments on 
item wording: they suggested adding the word ‘swollen’ to ‘arm’ for clarification; and, as patients 
are advised not to carry heavy objects, they suggested that the wording of the item on lifting should 
focus on the carrying of light objects. Following this pre-testing we revised the ULLQoL scale and 
took version 1, a 13-item scale was taken into the validation study. 
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3.2 Validation study 
We recruited 103 patients into the validation study over 81 weeks. We sent 57 patients retest scales, 
of which 46 (81%) were completed, returned and analysed. All 103 patients attended a follow-up 
visit after three to six months for responsiveness.  
 
In a pilot lasting ten weeks, we recruited 14 patients of the target of 20 patients. Interviews with the 
staff confirmed that the tested processes were suitable for data collection. A review of the 
completed 13-item ULLQoL scale (version 1) suggested that the wording of the item on sexuality may 
be inadequate to describe the concept in mind. So we changed its wording to replace the word 
‘sexuality’ to ‘femininity/masculinity’ aiming to more accurately reflect the concept under 
consideration by this question. We also responded to feedback from participants and clinical staff by 
adding a 'frequency’ question to capture the general effect of lymphedema on mood. We used the 
revised 14-item scale (ULLQoL version 2) for the remainder of the study. 
 
Of the 103 recruited patients, 100 (97%) were female, with a mean age of 60 years (SD 13).  Their 
ages spanned seven decades (Table 2). In 28 patients (27%) the swollen arm was less than 5% larger 
than the unaffected arm; in 37 patients (36%) the swollen arm was between 5% and 20% larger than 
the unaffected arm; in 29 patients (28%), the excess limb volume was between 21 and 40%; and for 
nine patients (9%) it was greater than 40%. The majority of patients had developed ULL secondary to 
breast cancer (95). . Other causes of ULL were non-Hodgkin’s lymphoma (1 patient), primary 
lymphoedema (1 patient), and secondary to infection (2 patients). There were missing data for 4 of 
the patients. Fifty-five patients (53%) had lymphedema of their dominant arm. The mean time 
between onset of ULL and recruitment into the study was 37 months (SD 12).   
 
3.3 Statistical analysis 
3.3.1 Item selection and assessment of underlying dimensions 
The 103 patients completed more than 95% of ULLQoL items (Table 3). Apart from the 14 pilot 
participants who necessarily completed version 1 rather than version 2 at baseline, one of the 103 
participants did not complete three items (Q4, Q5, Q7) at baseline as they missed the back of the 
double-sided sheet; and four participants did not complete Q9 at baseline for unknown reasons. At 
the second visit all 103 patients completed version 2. In total we needed to impute the lowest score 
for only 35 items across 206 questionnaires. All items showed the full range of responses with no 
floor or ceiling effects (Table 3). The item-total correlation coefficients for the 14 items ranged 
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between 0.26 and 0.62 thus meeting the pre-defined threshold of 0.2. We therefore included all 
items in the PCA of underlying dimensions.  
 
Initial analysis confirmed that the data were suitable for PCA, with KMO Index of 0.83 and Bartlett’s 
test significant at the 0.1% level. The unrotated exploratory analysis generated three components 
explaining 62% of the total variance. Some items loaded clearly on one component; but others had 
smaller loadings on more than one component. The scree-plot showed a clear elbow after two 
components, with components 1 and 2 explaining 54% of the total variance. Furthermore, the third 
component was uninterpretable, and only added 8% to the total variance explained. Hence, we 
opted for two components, within which most items loaded clearly. 
 
We then proceeded to oblique rotation, which allows for correlated components. Table 4 shows the 
resulting component loadings, the eigenvalues for each component and the variation explained by 
each component. Component 1 comprises items about ‘physical well-being’ aspects of ULL, while 
Component 2 addresses ‘emotional well-being’. The loadings exceeded 0.4 for all but two items: (9) 
“Do you feel down because of swollen arm?”; and (12) “How much time does your swollen arm 
cause pain or discomfort?” which had similar borderline loadings on both components.   
 
To allocate items 9 and 12, we observed the slightly higher item-total correlations when Q9 was in 
the emotional Component 2 and Q12 was in the physical Component 1 (Table 5), which also seems 
to improve face validity. All the resulting item-total correlation coefficients exceeded the threshold 
of 0.4 for removal. Thus, we recommend that Component 1 comprise nine physical well-being items 
and recommended Component 2 comprise five emotional well-being items. 
 
3.3.2 Calculation of scores of ULLQoL scale 
Total scores for the ULLQoL scale ranged from 0 to 49 with a mean score of 18.7 and standard 
deviation (SD) of 10.7. Though the distribution of scores was positively skewed at 0.50, the 
discrepancy was not substantial (Table 6).  
 
3.3.3 Psychometric properties of the ULLQoL scale 
The internal consistency of the ULLQoL scale achieved Cronbach’s alpha of 0.87, well above our 
target of 0.7. The two components also achieved good internal consistency: alpha was 0.87 for 
physical well-being and 0.77 for emotional well-being. The test-retest reliability of the ULLQoL scale 
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in 29 patients who reported no change in lymphedema over the two weeks from baseline was high 
at 0.93.  There was very little difference between their two sets of scores. 
 
The ULLQoL scale showed good construct validity with all eight predicted correlations with other 
PROMs achieving statistical significance and all correlations in the predicted direction. (Table7). 
Overall, the observed correlation between the two dimensions of the ULLQoL and the EQ-5D-3L 
utility score was as predicted, but the correlation between the ULLQoL physical dimension and the 
EuroQoL thermometer were smaller than predicted. The predicted correlations between the 
dimensions of the ULLQoL and the SF-36 PCS and MCS were all observed, except the correlation 
between the ULLQoL physical dimension and the MCS, which was larger than expected. The 
observed correlation for the two dimensions of the ULLQoL with % excess limb volume was weak as 
predicted.   
 
Of the 85 participants who completed the lymphoedema health transition question as well as the 
baseline and final questionnaires, 42 (49%) perceived their lymphedema as improved, and 33 (39%) 
perceived it as little changed, while ten (12%) perceived it as worse. Table 8 shows that the first 
group reported clearly improved ULLQoL scores (functional and emotional well-being) while the 
third group reported that all mean scores deteriorated. Furthermore, these changes reflected 
analogous changes in limb volume, with a decrease in limb volume when the patients reported 
improvement on the lymphoedema transition question, no change in limb volume when patients 
reported no change on the transition question, and increase in limb volume when they reported 
deterioration on the lymphedema transition question. All tests for linearity were significant at the 
1% level. Table 9 shows moderate to large effect sizes for the responsiveness of the ULLQoL scale. 
The one-half SD was 5.35 suggesting the minimal important change was in this range. 
 
4. Discussion 
The final version 2 of the ULLQoL scale showed good item completion, wide ranges of responses and 
consistency between items so we retained all 14 items. Only 35 items of data were missing and 
these were imputed with the lowest item value, giving rise to a very small potential bias. A variety of 
methods for handling missing data and imputation alternatives have been used to manage missing 
quality of life data [31-33]. All methods of imputation will introduce bias and arguably none of them 
are completely satisfactory [16]. Imputation of the lowest score is an acceptable method [16] that 
would have introduced a very small bias towards the better quality of life which resonates with our 
clinical experience and findings of qualitative research [34]. Nonetheless, the authors consider that 
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alternative imputation methods should be investigated in the future with the use of sensitivity 
analysis and multiple imputation methods. 
 
Psychometric analysis identified two believable dimensions –physical well-being (9 items) and 
emotional well-being (5 items). Given the dearth of literature at the time of instrument 
development, the scale structure of the ULLQoL relied on the findings of exploratory PCA and a 
definition of HRQoL as opposed to setting up a hypothesis-driven factor structure to be tested 
against the data. Ideally, this first psychometric evidence needs confirmatory analysis on another 
cohort of patients with ULL, to explore the factor structure further and specifically investigate the 
heterogeneity of the physical well-being dimension. Using the findings of in-depth interviews, our 
understanding of the impact of ULL on HRQoL was extended [34]. The finding that symptoms of 
upper limb lymphoedema had an array of physical, emotional and social impacts on HRQoL supports 
the item content validity and scale structure of the ULLQoL [34].   In addition, the labelling of the 
physical well-being dimension may be reviewed in future validation studies to ensure there is no 
problem with the naming given its use in other PROMs such as the SF-36, with additional qualitative 
research to validate the items and structure of the ULLQoL. 
 
The resulting upper limb lymphedema-specific QoL measure showed excellent internal consistency 
and test-retest reliability, and good construct validity, with the generic SF-36 and EQ-5D-3L as 
constructs. Nevertheless, we recommend further analysis of the test-retest reliability using an 
objective measure for stability, and further larger studies of construct validity, particularly against 
more specific constructs, for example, a clinician’s global assessment of well-being, or severity of 
lymphedema using the International Society of Lymphology’s staging system [3]. The vast majority of 
the patients in the validation study had developed ULL secondary to breast cancer. The authors 
consider that the ULLQoL may be appropriate for a broader target group with ULL, but this would 
have to be tested in further validation studies.  
 
Before our definitive analysis we predicted only very weak correlation between the physical and 
emotional dimensions of the ULLQoL scale and limb volume, the usual measures of severity of 
lymphedema. Both Passik et al. [35] and Woods [5] had reported that limb volume did not influence 
patients’ emotional well-being. Fortunately, we observed the predicted very weak correlation. 
Though the assessment of limb size is important in clinical assessment of ULL, the ULLQoL scale now 
provides complementary, holistic assessment that takes full account of the wide range of morbidity.  
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The ULLQoL scale was responsive to self-reported change in lymphedema, with tests for linearity 
being significant at the 1% level. It therefore provides a useful measure for monitoring patients in 
both clinical practice and research, suggesting that patients are very much aware of changes in the 
swollen limb. Future investigation of the minimal clinically important differences on the ULLQoL 
scale would enhance this finding. 
 
In conclusion, the first evidence of psychometric properties for the ULLQoL scale suggest the 
measure is a valid, reliable, consistent and responsive PROM for assessing HRQoL in breast cancer-
related lymphoedema.  It is the most robust measure for ULL as assessed by Terwee’s quality criteria 
[10] and the COSMIN checklist [11]. It is short, takes less than five minutes to complete, and is easy 
to use in clinical practice and research. We therefore recommend that ‘Best Practice for the 
Management of Lymphedema’ [3] use the ULLQoL to improve clinical assessment. Furthermore, the 
regular collection of ULLQoL data has the potential to improve patient-clinician communication and 
even patients’ HRQoL. To this end, the ULLQoL scale is freely available for use in clinical practice or 
research.  
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Table 1. Summary of known lymphoedema-specific HRQoL measures 
 
HRQoL measure Developers Specificity of measure Year Number 
of items 
Domains 
WCLS Mirolo et al. Cancer-related 1995 5 No named domain 
FACT-B+4 Coster et al. Breast cancer-related arm 
morbidity 
2001 5 No named domain 
ULL27 Launois et al. Upper limb lymphoedema 2000 27 Physical 
Psychological 
Social 
Weiss and Spray 
QoL 
Weiss & Spray All lymphoedema 2002 17 Physical 
Psychological 
Functional 
LQOLI Kristjanson 
(not 
published) 
All lymphoedema 2004 188 Physical 
Emotional 
Social 
Practical 
LYMQOL-arm Keeley et al. Upper limb lymphoedema 2004 38 Symptoms 
Body image & 
appearance 
Function 
Mood 
FLQA-l Augustin et al. All lymphoedema 2005 92 Physical complaints 
Everyday life 
Social life 
Emotional well-being 
Stress due to 
management 
Satisfaction with 
different areas of life 
Satisfaction with 
work &household 
LyQLI Klernas et al. All lymphoedema 2015 45 Physical 
Emotional 
Social 
Practical 
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Table 2. Characteristics of recruited patients in the validation study 
 
Demographic data Number of patients (total = 103) 
Gender:   
Female 100 (97%) 
Male 3 (3%) 
    
Age:   
20-29 years 1 (1%) 
30-39 years 3 (3%) 
40-49 years 15 (15%) 
50-59 years 34 (33%) 
60-69 years 20 (19%) 
70-79 years 21 (20%) 
80 -89 years 9 (9%) 
Mean age (SD) 60.5 years (13.0) 
Range 23 to 86 years 
Percentage excess limb volume   
<5% 28 (27%) 
0 - 20% 37 (36%) 
21 - 40% 29 (28%) 
≥41% 9 (9%) 
Cause of upper limb lymphoedema:   
Breast cancer 102 (99%) 
Non-Hodgkin’s lymphoma 1 (1%) 
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Table 3. Item completion rates and frequency of endorsement at first visit  
_______________________________________________________________________________ 
Item *                                         Missing                Floor (%)                 Ceiling (%)  
                                  n (%)                 (best health)         (worst health) 
______________________________________________________________________________ 
Q1.   Interfere with normal work activities            0          24.3               2.9 
Q2.   Interfere with normal leisure activities            0          27.2                       4.9 
Q3.   Interfere with self-care             0          46.6                           1.0 
Q4.   Interfere with dressing and undressing            1 (0.97)         57.8                           1.0 
Q5.   Interfere with sleep                             1 (0.97)         34.3                           2.0 
Q6.   Influences femininity or masculinity vs3 §       0          61.8                           2.2 
Q7.   Interfere with lifting and carrying            1 (0.97)         10.8          15.7 
Q8.   Interfere with reaching high objects            0         23.3           14.6 
Q9.   Feel down because of swollen arm vs3§          4 (4.40)        35.9             1.0 
Q10. Feel down because restricts clothing             0         44.7             8.7 
         you would like to wear   
Q11. How much time swollen arm stops you           0        41.7             9.7 
         wearing clothing would like to wear 
Q12. How much time swollen arm causes             0        13.6                            8.7 
         pain or discomfort 
Q13. How much time feel aware of swollen arm      0        12.6           13.6 
Q14. How much time feel self-conscious or 
         embarrassed in public              0        55.3             6.8 
________________________________________________________________________________  
§ (Q6 and Q9 only included in the 14-item version which was issued after the pilot period to 91 patients)  
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Table 4. Principal component analysis with oblique rotation: factor loadings of ULLQoL scale 
 
Component 
 
Items 
1 
Physical 
well-being 
2 
Emotional 
well-being 
1. To what extent did your swollen arm interfere with your normal work activities? 0.818 
2. To what extent did your swollen arm interfere with your normal leisure activities? 0.739 
3. To what extent did your swollen arm interfere with your self-care? 0.852 
4. To what extent did your swollen arm interfere with dressing and undressing? 0.780 
5. To what extent did your swollen arm interfere with your sleep? 0.665 
6. To what extent did you feel your femininity or masculinity was influenced by your  
     swollen arm? 0.664 
7. To what extent did your swollen arm interfere with lifting or carrying light 
objects? 0.674 
8. To what extent did your swollen arm interfere with reaching high objects? 0.851 
9. To what extent did you feel down because of your swollen arm? 0.317 0.375 
10. To what extent did you feel down because your swollen arm has restricted the  
       clothing that you would like to wear? 0.664 
11. How much of the time did your swollen arm stop you wearing clothing that you  
      would like to wear? 0.869 
12. How much of the time did your swollen arm cause you pain or discomfort? 0.348 0.327 
13. How much of the time were you aware of your swollen arm? 0.403 
14. How much of the time did your swollen arm cause you to feel self-conscious or  
      embarrassed in public?   0.870 
Eigenvalue 5.5 2.0 
Percentage of variance explained by component 39.3% 14.3% 
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Table 5. Corrected item-total correlations for the ULLQoL scale  
 
 
Items 
Corrected 
item-total 
correlation 
Physical well-being component (including Q12) 
 
1. To what extent did your swollen arm interfere with your normal work activities? 0.71 
2. To what extent did your swollen arm interfere with your normal leisure activities? 0.68 
3. To what extent did your swollen arm interfere with your self-care? 0.73 
4. To what extent did your swollen arm interfere with dressing and undressing? 0.68 
5. To what extent did your swollen arm interfere with your sleep? 0.53 
7. To what extent di your swollen arm interfere with lifting or carrying light objects? 0.57 
8. To what extent did your swollen arm interfere with reaching high objects? 0.77 
12. How much of the time did your swollen arm cause you pain or discomfort? 0.46 
13. How much of the time were you aware of your swollen arm? 0.45 
Emotional well-being component (including Q9) 
 
6. To what extent did you feel your femininity or masculinity was influenced by your  
     swollen arm? 
0.60 
9. To what extent did you feel down because of your swollen arm? 0.46 
10. To what extent did you feel down because your swollen arm has restricted the  
       clothing that you would like to wear? 
0.60 
11. How much of the time did your swollen arm stop you wearing clothing that you  
      would like to wear? 
0.60 
14. How much of the time did your swollen arm cause you to feel self-conscious or  
      embarrassed in public?  
0.59 
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Table 6. ULLQoL scale component and total scores 
 
ULLQoL scores Mean score (SD) Range Skewness 
ULLQoL physical well-being component scores 13.5 (7.7) 0 to 30
a 
+ 0.391 
ULLQoL emotional well-being component scores 5.2 (4.8) 0 to 19
b 
+ 0.921 
ULLQoL total scores 18.7 (10.7) 0 to 49
c
 + 0.504 
a
 Maximum range 0 to 36; 
b
 Maximum range 0 to 20; 
c
 Maximum range 0 to 56. 
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Table 7. Predicted and observed correlations between ULLQoL scale components and existing measures 
 
  ULLQoL Physical 
well-being component 
ULLQoL Emotional 
well-being component 
EQ-5D-3L 
Utility score 
EuroQoL 
thermometer 
SF-36 
PCS 
SF-36 
MCS 
% Excess  
limb volume 
ULLQoL Physical  
well-being component 
Predicted  +ve 
moderate 
-ve 
moderate 
-ve 
moderate 
-ve 
moderate 
-ve 
weak 
+ve 
very weak 
Observed  + 0.45 
(weak) 
- 0.59 
(moderate) 
- 0.44 
(weak) 
- 0.57 
(moderate) 
- 0.41 
(weak) 
+ 0.12 
(very weak) 
ULLQoL Emotional 
well-being component 
Predicted   -ve 
weak 
-ve 
weak 
-ve 
very weak 
-ve 
weak 
+ve 
very weak 
Observed   - 0.50 
(weak) 
- 0.46 
(weak) 
- 0.31 
(weak) 
- 0.43 
(weak) 
+ 0.18 
(very weak) 
 
ULLQoL:  low score shows better QoL. SF-36: high score shows better QoL. EQ-5D-3L: high score shows better QoL.  
‘+ve’ indicates the change in score was in the same direction; ‘-ve’ indicates that the change in score was in different directions 
Correlations greater than 0.7 show strong relationships; between 0.5 and 0.7 show moderate relationships; between 0.3 and 0.5 show weak relationships; 
and less than 0.3 show very weak relationships [26] 
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Table 8. Correlation of mean change in ULLQoL scores and limb volume by lymphoedema transition 
question 
 Lymphoedema transition question  
Mean change  
(standard deviation) 
Better 
(n=42) 
Same 
(n=33) 
Worse 
(n=10) 
F-test for linearity 
ULLQoL physical  
well-being component 
a
 
-8.9 (19.0) -3.3 (13.9) 8.4 (13.8) 4.58** 
ULLQoL emotional  
well-being component 
a
 
-5.4 (17.7) 2.8 (18.2) 15.0 (27.7) 5.02** 
% change in limb 
volume 
-4.8 (11.8) -0.7 (5.7) 11.7 (14.6) 10.39** 
 
a Lower ULLQ scores show better quality of life.  
** Statistically significant at 1% level. 
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Table 9. Mean Change in ULLQoL scores and limb volume: Modified Standardised Response Means 
 
 Lymphoedema transition question 
Better (n = 42) Worse (n = 10) 
     Mean change  
(SD of change scores) 
MSRM Mean change  
(SD of change scores) 
MSRM 
ULLQoL physical  
well-being component 
a
 
-8.9 (19.0) 0.64 8.4 (13.8) 0.61 
ULLQoL emotional  
well-being component 
a
 
-5.4 (17.7) 0.30 15.0 (27.7) 0.83 
% change in limb 
volume 
-4.8 (11.8) 0.84 11.7 (14.6) 2.06 
 
MSRM: Modified Standardised Response Mean 
a 
Lower ULLQoL scores show better QoL 
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What is new? 
Key finding:  
• The 14-item ULLQoL scale is a valid, reliable, consistent and responsive PROM for assessing 
quality of life in upper limb lymphedema. 
What this study adds to what was known?  
• Other lymphedema-specific measures exist, but when assessed against Terwee et al.’s 
(2007) quality criteria and the COSMIN checklist (Mokkink et al., 2010) for methodological 
quality none was adjudged robust.  
• The ULLQoL scale was developed and validated rigorously, and is short, taking less than five 
minutes to complete, and is easy to use in clinical practice and research. 
What is the implication and what should change now?  
• The ULLQoL scale has potential for use in clinical practice and research to assess QoL 
alongside limb volume.  
• We recommend including the ULLQoL scale in ‘Best Practice for the Management of 
Lymphedema’ 
